FEWER than one in ten of the world’s billion obese people can access weight-loss jabs, according to the World Health Organisation. High costs, limited production and supply chain problems are preventing the vast majority of overweight people who would benefit from accessing what can be life-saving GLP-1 drugs. The WHO has already classed them as…
